Coronary Artery Bypass Graft. Atherosclerotic Heart Disease
Conditions
Interventions
Intervention 1: Patients in the intervention group received 150 mg pregabalin, 2 hours before surgery and 75 mg pregabalin at the first, second and third days after surgery in the hours of 9 am and 9
Treatment - Drugs
Placebo
Patients in the intervention group received 150 mg pregabalin, 2 hours before surgery and 75 mg pregabalin at the first, second and third days after surgery in the hours of 9 am and 9 pm .
Patients in the control group received one capsule placebo , 2 hours before surgery and at the first, second and third days after surgery in the hours of 9 am and 9 pm
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients who undergo coronary artery bypass graft surgery. exclusion criteria: EF 1.5, BMI > 35, chronic alcohol consumers, drug addicts, epileptic patients, patients with insulin dependent diabetes mellitus ', recent use of gabapentin, uncontrolled blood pressure, liver failure, the sensitivity of the Pregabalin, return to the operating room during the study period, the patient's re-intubation during the first 3 days after the surgery, mortality during the first 3 days.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: Twice at Three Days after Surgery. Method of measurement: ,VAS(Visual Analogue Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Agitation. Timepoint: Twice at Three Days after Surgery. Method of measurement: Richmond agitation sedation scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSudabeh Emami
Shiraz University of Medical Sciences
Outcome results
None listed